Across TCGA pan-cancer cohorts, CLCN3P1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CLCN3P1 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CLCN3P1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CLCN3P1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.
UCEC, LUAD, and PRAD are the cancer types where CLCN3P1 Mutation most reproducibly stratifies survival.